• 한국수의병리학회:학술대회논문집
• /
• 한국수의병리학회 2003년도 추계학술대회초록집
• /
• pp.9-9
• /
• 2003

Primary canine lung tumor is very uncommon and account for only about 1％ of all cancers diagnosed [1]. The average age at diagnosis is about 10 years and no breed or sex predilection has been confirmed. Almost all primary cancers of the lungs are carcinomas, the most common being adenocrcinoma. This study describes primary lung tumor in a dog that is accompanied by cerebellar metastasis with related neurologic signs. (omitted)

• 한국식품과학회지
• /
• 제31권4호
• /
• pp.1065-1070
• /
• 1999

참취뿌리의 에탄올 추출물과 용매 분획물에 대한 생리활성 효과를 밝히기 위해 항돌연변이성 및 암세포 성장억제효과를 실시한 결과 에탄올 추출물 자체의 돌연변이성은 없었다. 직접변이원인 N-methyl-N'-nitro-N-nitrosoguanidine(MNNG)에 대해서는 Salmonella typhimurium TA100의 경우 에탄올 추출물이 79%, 에틸아세테이트 분획물은 82%의 억제효과를 나타내었다. 4-Nitroquinoline-1-oxide(4NQO)에 대해서는 Salmonella typhimurium TA98에서 에탄올 추출물이 48%, 에틸 아세테이트 분획물은 60%의 억제효과를 보였다. 한편 간접 변이원인 benzo(${\alpha}$)pyrene[B(${\alpha}$)P]에 대해서는 에틸아세테이트 분획물의 경우 TA98에서는 78%, TA100에서는 85%의 높은 억제활성을 나타내었다. 그리고 3-amino-1,4-dimethyl-5H-pyrido(4,3-b)indole(Trp-P-1)에 대해서는 TA98에서 89%의 높은 억제효과를 보였다. 한편 참취 에탄올 추출물에 대한 암세포 성장억제 실험에서도 chronic myelogenous leukemia (K562), human gastric carcinoma (KATOIII), human hepatocellular carcinoma (Hep3B) 및 human breast adenocarcioma (MCF-7)에 대하여 높은 세포독성을 나타내었으며 용매 분획물의 경우 KATOIII 세포에서는 모든 분획물이 높은 세포독성을 나타내었으나 그외세포에 대해서는 물분획물을 제외한 에틸아세테이트, 부탄올 및 클로로포름 분획물이 높은 세포독성을 나타내었다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권17호
• /
• pp.7653-7658
• /
• 2015

Background: NAD(P)H:quinone oxidoreductase 1 (NQO1) is part of the antioxidant defence system involved in detoxification. This study aimed to analyze the influence of NQO1 (C609T) genetic polymorphism in non small cell lung cancer (NSCLC)as a putative risk factor. Materials and Methods: Present study included 100 cases of NSCLC (adenocarcinoma) patients and 100 age and sex matched healthy controls. NQO1 (C609T) genotyping was performed by allele specific PCR for assessment of putative associations with clinical outcome and genotypes of. The association of the polymorphism with the survival of NSCLC patients' was analyzed by Kaplan-Meier method. Results: In Indian NSCLC (adenocarcinoma) patients increased risk of developing NSCLC was found to be associated with NQO1 609TT genotype [OR 3.68(0.90-14.98), RR 2.04(0.78-5.31)] for CT [OR 2.91(1.58-5.34), RR 1.74(1.23-2.44) p=0.0005 for CT], for CT+TT [ OR 3.26(1.82-5.82), RR 1.87(1.34-2.61) p<0.0001 for CT+TT]. A significant difference (p=0.0009) was observed in genotype distribution among cases and healthy controls. Patients with CT+TT genotype exhibited a significant poor overall survival compared with patients displaying homozygous CC genotype (p=0.03) and when survival independently compared with CC, TT and CT genotype was also found to be significantly associated (p=0.02). Overall median survival times were CT 6.0 months, TT 8.2 months, and CT + TT (6.4 months)]. Conclusions: The present study revealed that NQO1 CT, TT and CT+TT genotypes may be associated with clinical outcome and risk of developing NSCLC in the Indian population.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권9호
• /
• pp.4037-4040
• /
• 2015

Objective: To explore the clinical efficacy and toxic and side effects of recombinant human endostatin (rhendostatin/endostar) combined with chemotherapy in the treatment of advanced gastric cancer. Materials and Methods: A total of 70 patients with advanced gastrointestinal adenocarcioma confirmed by histopathology and/or cytological examination were divided into group A (37 patients) and group B (33 patients). Patients in group A were given intravenous drip of 15 mg endostar added into 500 mL normal saline, once every other day until the cessation of chemotherapy or patients' maximal tolerance to chemotherapy. Patients in group B received chemotherapy alone. Two groups selected the same chemotherapy regimens. FOLFIRI scheme: 90-min intravenous drip of $180mg/m^2$ irinotecan, intravenous drip of $200mg/m^2$ calcium folinate (CF) and $400mg/m^2$ 5-fluorouracil (5-Fu) on d1, and continuous intravenous pumping of 2 $400mg/m^2$ 5-Fu for 46 h. FOLFOX4 scheme: intravenous injection of $85mg/m^2$ oxaliplatin (L-OHP), $200mg/m^2$ calcium folinate (CF) and $400mg/m^2$ 5-FU on d1 for 2 h, and then continuous intravenous pumping of 2 $400mg/m^2$ 5-Fu for 46 h. XELOX scheme: oral administration of 1 $500mg/m^2$ xeloda (or tegafur 50~60 mg) in twice during d1~14 and intravenous drip of $135mg/m^2$ L-OHP on d1 for 2 h. The modified FOLFOX scheme: intravenous injection of $135mg/m^2$ L-OHP on d1 for 2 h, $200mg/m^2$ CF and 1.0 g tegafur during d1~5. Whereas, control Group B received chemotherapy regimens which were same as Group A, but no addition of endostar. Before chemotherapy, patients were given intravenous injection of 8 mg ondansetron, intramuscular injection of 10 mg metoclopramide and 20 mg diphenhydramine for prevention of vomiting, protection of liver and stomach as well as symptomatic supportive treatment. One cycle was 21 d, 4~6 cycles in total. The efficacy was evaluated every 2 cycles. Results: 32 patients in Group A could be evaluated, and the response rate (RR) and disease control rate (DCR) were 59.38% and 78.13%, respectively. 31 patients in Groups could be evaluated, and the RR and DCR were 32.26% and 54.84%, respectively. The differences between 2 groups were significant. The toxic effects include myelosuppression, gastrointestinal reaction, fatigue, cardiotoxicity and peripheral neurotoxicity. Conclusions: Preliminary observations show that endostar (once every other day) combined with chemotherapy is effective in the treatment of advanced gastrointestinal cancer, with low toxic effects, good tolerance, deserving further study.